Aprea logo 445pt.png
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
November 04, 2021 16:15 ET | Aprea Therapeutics
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
October 25, 2021 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American...
The MDS Foundation Celebrates MDS World Awareness Day With Their 4th Annual Move for MDS 5k Walk at Boston Common and Virtually Around the World
October 20, 2021 10:05 ET | MDS Foundation, Inc.
YARDVILLE, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- The MDS Foundation, a global non-profit advocacy organization is proud to announce its fourth annual Move for MDS walk at Boston Common on Sunday,...
LIXTE.jpg
Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
August 17, 2021 09:25 ET | Lixte Biotechnology Holdings, Inc.
A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) --...
Aprea logo 445pt.png
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
July 21, 2021 08:00 ET | Aprea Therapeutics
58% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplant BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Aprea logo 445pt.png
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
December 28, 2020 08:00 ET | Aprea Therapeutics
The trial failed to meet its primary endpoint of complete remission (CR) rateCR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach statistical significance ...
Geron-logo-black-xsmall.png
Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events
November 05, 2020 16:05 ET | Geron Corporation
FOSTER CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results
August 12, 2020 16:05 ET | Onconova Therapeutics, Inc.
INSPIRE Phase 3 trial survival events reachedTopline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET NEWTOWN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE)...
Aprea logo 445pt.png
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
August 11, 2020 16:15 ET | Aprea Therapeutics
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020
August 07, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...